MK-801-induced and scopolamine-induced hyperactivity in rats neonatally treated chronically with MK-801

Behavioural Pharmacology

Volumn 24, Issue 8, 2013, Pages 678-683

  Furuie, Hiroki ^a   Yamada, Kazuo ^a   Ichitani, Yukio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Chronic neonatal treatment; Locomotor activity; MK 801; N methyl D aspartate receptor; Rat; Scopolamine

Indexed keywords

DIZOCILPINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SCOPOLAMINE; SODIUM CHLORIDE;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; GLUTAMATERGIC TRANSMISSION; HYPERACTIVITY; LOCOMOTION; NEUROTRANSMISSION; NEWBORN; NONHUMAN; RAT;

ANIMALS; ANIMALS, NEWBORN; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; HYPERKINESIS; MALE; MUSCARINIC ANTAGONISTS; RATS; SCOPOLAMINE HYDROBROMIDE;

EID: 84888198516     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000003     Document Type: Article

References (42)

1. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554. (Pubitemid 28311969)
2. Bauer EP, Schafe GE, LeDoux JE (2002). NMDA receptors and L-type voltagegated calcium channels contribute to long-term potentiation and different components of fear memory formation in the lateral amygdala. J Neurosci 22:5239-5249. (Pubitemid 37465637)
3. Boctor SY, Ferguson SA (2010). Altered adult locomotor activity in rats from phencyclidine treatment on postnatal days 7, 9 and 11, but not repeated ketamine treatment on postnatal day 7. Neurotoxicology 31:42-54.
4. Chapman CA, Yeomans JS, Blaha CD, Blackburn JR (1997). Increased striatal dopamine efflux follows scopolamine administered systemically or to the tegmental pedunculopontine nucleus. Neuroscience 76:177-186. (Pubitemid 26407947)
5. Dall'Olio R, Facchinetti F, Contestabile A, Gandolfi O (1994). Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat. Neuroscience 63:451-455. (Pubitemid 24357370)
6. Du Bois TM, Hsu C-W, Li Y, Tan YY, Deng C, Huang X (2008). Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade. Neurochem Res 33:1224-1231.
7. Du Bois TM, Deng C, Han M, Newell KA, Huang X (2009a). Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade. Eur Neuropsychopharmacol 19:256-265.
8. Du Bois TM, Newell KA, Han M, Deng C, Huang X (2009b). Perinatal PCP treatment alters the developmental expression of prefrontal and hippocampal muscarinic receptors. Prog Neuropsychopharmacol Biol Psychiatry 33:37-40.
9. Elhardt M, Martinez L, Tejada-Simon MV (2010). Neurochemical, behavioral and architectural changes after chronic inactivation of NMDA receptors in mice. Neurosci Lett 468:166-171.
10. Facchinetti F, Ciani E, Dall'Olio R, Virgili M, Contestabile A, Fonnum F (1993). Structural, neurochemical and behavioural consequences of neonatal blockade of NMDA receptor through chronic treatment with CGP 39551 or MK-801. Brain Res Dev Brain Res 74:219-224. (Pubitemid 23205440)
11. Facchinetti F, Dall'Olio R, Ciani E, Sparapani M, Virgili M, Contestabile A (1994). Long-lasting effects of chronic neonatal blockade of N-methyl-D-aspartate receptor through the competitive antagonist CGP 39551 in rats. Neuroscience 60:343-353. (Pubitemid 24175206)
12. Fernández-Teruel A, Giménez-Llort L, Escorihuela RM, Gil L, Aguilar R, Steimer T, et al. (2002). Early-life handling stimulation and environmental enrichment: Are some of their effects mediated by similar neural mechanisms? Pharmacol Biochem Behav 73:233-245. (Pubitemid 34667035)
13. Gorter JA, de Bruin JP (1992). Chronic neonatal MK-801 treatment results in an impairment of spatial learning in the adult rat. Brain Res 580:12-17.
14. Gorter JA, Botterblom MH, Feenstra MG, Boer GJ (1992a). Chronic neonatal NMDA receptor blockade with MK-801 alters monoamine metabolism in the adult rat. Neurosci Lett 137:97-100.
15. Gorter JA, Veerman M, Mirmiran M (1992b). Hippocampal neuronal responsiveness to NMDA agonists and antagonists in the adult rat neonatally treated with MK-801. Brain Res 572:176-181.
16. Halpern JH (2004). Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 102:131-138. (Pubitemid 38681012)
17. Harris LW, Sharp T, Gartlon J, Jones DNC, Harrison PJ (2003). Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neurosci 18:1706-1710. (Pubitemid 37215123)
18. Hirasawa T, Wada H, Kohsaka S, Uchino S (2003). Inhibition of NMDA receptors induces delayed neuronal maturation and sustained proliferation of progenitor cells during neocortical development. J Neurosci Res 74:676-687. (Pubitemid 37475448)
19. Hyde TM, Crook JM (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 22:53-63. (Pubitemid 32695509)
20. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, et al. (1999). Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283:70-74. (Pubitemid 29044848)
21. Jentsch JD, Tran A, Taylor JR, Roth RH (1998). Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology (Berl) 138:89-95. (Pubitemid 28319052)
22. Johnson KM, Snell LD (1985). Effects of phencyclidine (PCP)-like drugs on turning behavior, 3H-dopamine uptake, and 3H-PCP binding. Pharmacol Biochem Behav 22:731-735. (Pubitemid 15120519)
23. Kawabe K, Iwasaki T, Ichitani Y (2007). Repeated treatment with N-methyl-Daspartate antagonists in neonatal, but not adult, rats causes long-term deficits of radial-arm maze learning. Brain Res 1169:77-86. (Pubitemid 47374093)
24. Kawabe K, Ichitani Y, Iwasaki T (1998). Effects of intrahippocampal AP5 treatment on radial-arm maze performance in rats. Brain Res 781: 300-306. (Pubitemid 28082875)
25. Komuro H, Rakic P (1993). Modulation of neuronal migration by NMDA receptors. Science 260:95-97. (Pubitemid 23122752)
26. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
27. Mathur A, Shandarin A, LaViolette SR, Parker J, Yeomans JS (1997). Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus. Brain Res 775:144-155. (Pubitemid 28020499)
28. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927. (Pubitemid 27155025)
29. Morris RG, Anderson E, Lynch GS, Baudry M (1986). Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319:774-776. (Pubitemid 16145031)
30. O'Mahony SM, Hyland NP, Dinan TG, Cryan JF (2011). Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl) 214:71-88.
31. Singer P, Yee BK (2012). Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice. Pharmacol Biochem Behav 101:107-114.
32. Sircar R (2003). Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-D-aspartate receptor upregulation. Int J Dev Neurosci 21:159-167. (Pubitemid 36444541)
33. Sircar R, Soliman KFA (2003). Effects of postnatal PCP treatment on locomotor behavior and striatal D2 receptor. Pharmacol Biochem Behav 74:943-952. (Pubitemid 36351657)
34. Snell LD, Yi SJ, Johnson KM (1988). Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol 145:223-226. (Pubitemid 18028508)
35. Stefani MR, Moghaddam B (2005). Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 57:433-436. (Pubitemid 40215775)
36. Tandon R, Greden JF, Haskett RF (1993). Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls. Schizophr Res 9:19-23. (Pubitemid 23076885)
37. Uehara T, Sumiyoshi T, Seo T, Matsuoka T, Itoh H, Suzuki M, et al. (2010). Neonatal exposure to MK-801, an N-methyl-D-aspartate receptor antagonist, enhances methamphetamine-induced locomotion and disrupts sensorimotor gating in pre- and postpubertal rats. Brain Res 1352:223-230.
38. Venable N, Kelly PH (1990). Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice. Psychopharmacology (Berl) 100:215-221. (Pubitemid 20038565)
39. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001). Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107:535-550. (Pubitemid 33097492)
40. Wedzony K, Fijal K, Mackowiak M, Chocyk A, Zajaczkowski W (2008). Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia. Neuroscience 153:1370-1379.
41. Wozniak DF, Olney JW, Kettinger L 3rd, Price M, Miller JP (1990). Behavioral effects of MK-801 in the rat. Psychopharmacology (Berl) 101:47-56. (Pubitemid 20124741)
42. Zeng XP, Le F, Richelson E (1997). Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321:349-354. (Pubitemid 27105938)